These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9884918)

  • 41. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
    Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
    Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years.
    Hauck EW; Altinkilic BM; Schroeder-Printzen I; Rudnick J; Weidner W
    Andrologia; 1999; 31 Suppl 1():99-103. PubMed ID: 10643527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction.
    Soderdahl DW; Thrasher JB; Hansberry KL
    Br J Urol; 1997 Jun; 79(6):952-7. PubMed ID: 9202565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Intracavernous injection: a treatment modality for erectile dysfunction].
    Uche-Holub E; Thierling U; Giessing M; Neumann NJ
    Hautarzt; 2013 Apr; 64(4):232-3. PubMed ID: 23576167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction.
    Canale D; Giorgi PM; Lencioni R; Morelli G; Gasperi M; Macchia E
    Int J Androl; 1996 Feb; 19(1):28-32. PubMed ID: 8698535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The interest of early rehabilitation with intracavernous injections following complete prostatectomy].
    Amar E
    Presse Med; 2005 Jul; 34(13 Suppl):15-8. PubMed ID: 16158024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction.
    Montorsi F; Guazzoni G; Bergamaschi F; Ferini-Strambi L; Barbieri L; Rigatti P
    J Urol; 1993 May; 149(5 Pt 2):1291-5. PubMed ID: 7683061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracavernous self-injection therapy for the treatment of erectile dysfunction.
    Chiang HS; Wen TC; Wu CC; Chiang WH
    J Formos Med Assoc; 1992 Sep; 91(9):898-901. PubMed ID: 1363391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Initial experiences with prostaglandin E1 and PGE1 prepared injections].
    Mattarelli G; Leibundgut B
    Helv Chir Acta; 1991 Sep; 58(3):335-7. PubMed ID: 1769856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
    Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.
    Lea AP; Bryson HM; Balfour JA
    Drugs Aging; 1996 Jan; 8(1):56-74. PubMed ID: 8785470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction.
    Colli E; Calabrò A; Gentile V; Mirone V; Soli M
    Eur Urol; 1996; 29(1):59-62. PubMed ID: 8821692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Intracavernous injections of prostaglandin E1 in the treatment of erection disorders].
    Beretta G; Zanollo A; Portalupi W
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):481-5. PubMed ID: 1838836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.